The effect of tegaserod on quality of life in patients having co-existence of irritable bowel syndrome and fibromyalgia
Yükleniyor...
Tarih
2009
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Abstract: Amaç. Bu çalışmanın amacı irritabl barsak sendromu ile birlikte fibromyaljisi olan hastalarda tegaserodun semptomlar ile yaşam kalitesine etkisini araştırmaktır. Yöntem. Çalışma Mart 2005 ve Eylül 2005 tarihleri arasında yapıldı. Konstipasyon-baskın irritabl barsak sendromu ile birlikte fibromyaljili hasta grubu (28 bayan) ve yalnızca konstipasyon-baskın irritabl barsak sendromulu hasta grubu (28 bayan) oluşturuldu. Yaşam kalitesinin değerlendirilmesinde WHOQOL (Dünya Sağlık Örgütü yaşam kalitesi ölçeği)’nin Türkçe kısa versiyonu olan WHOQOL-BREF-TR kullanıldı. Ağrının şiddetinin değerlendirilmesinde ise görsel analog ölçek kullanıldı. Her iki gruba da tegaserod 6 mg tablet kahvaltı ve akşam yemeğinden yarım saat önce almaları tavsiye edilerek verildi. Hastalar tedavinin 1. ve 3. aylarında kontrole çağırıldılar. Kontrole geldiklerinde WHOQOL-BREF-TR’deki soruları cevaplamaları istendi. Bulgular. Toplam yaşam kalitesi puanları değerlendirildiğinde her iki grubun tedavi öncesi değerleri arasında anlamlı bir farklılık saptanmadı. Ancak her iki grubun birinci ve ikinci aylarındaki değerleri arasındaki fark anlamlı bulundu (p<0,05). Sonuçlar. WHOQOL-BREF-TR yaşam kalitesi toplam puanları tedavi ile yalnızca konstipasyon baskın irritabl barsak sendromu olan hastalarda arttı. Konstipasyon ve fibromyalji sendromunun birlikte olduğu hastalarda ise artmadı. Bunun nedeni ölçekle ilgili problemler olabilir. Çünkü ölçek psikolojik, çevresel ve sosyal alanları içermektedir ve irritabl barsak sendromuna fibromyalji de eklenince bu tür hastalara tedavide ek psikolojik ve sosyal destek tedavisi verilmesi gerekebilir. Çalışmamızda ilaç ile ilişkili herhangi bir kardiyovasküler yan etkiye rastlanmamakla birlikte kardiyovasküler yan etkileri nedeniyle çalışmanın tamamlanmasından sonra 2007 yılında tegaserodun kullanımı yasaklandı.
Abstract: Aim. The aim of this study is to investigate the effect of tegaserod on symptoms and quality of life in patients who have irritable bowel syndrome and fibromyalgia co-existence. Methods. The study was performed between the time March 2005 and September 2005. Two groups were formed; constipation predominant irritable bowel syndrome (IBS-C) patients having co-existence of fibromyalgia (IBS-C plus FMS group, 28 female patients) and IBS-C patients without fibromyalgia (IBS-C group, 28 female patients). Turkish brief version of WHOQOL (World Health Organization Quality of Life) named as WHOQOL-BREF-TR scale was used to determine the QoL of patients. Visual anolog scale was used to determine the severity of pain. Tegaserod 6 mg tablet was given to the study groups administered ½ hours before breakfast and dinner. They were called for control visits at the first and second months of therapy. WHOQOL-BREF-TR scale was answered by patients during these visits. Results. When the total QoL scores of the study groups were compared, there was no difference between the pretreatment values of study groups. But we found a significant difference when the first and second month values of the study groups were compared. (p<0.05). Conclusions. QoL increased in only IBS-C patients but not in patients with a co-existence of fibromyalgia and IBS-C. The reason for this result can be explained by scale related problems as it only determines psychological, environmental and social areas and social and psychological additional support therapies could be required for IBS-C and FMS patients. Although there was no cardiovascular side effects of tegaserod in our study subjects, the drug was withdrawn from market in 2007.
Abstract: Aim. The aim of this study is to investigate the effect of tegaserod on symptoms and quality of life in patients who have irritable bowel syndrome and fibromyalgia co-existence. Methods. The study was performed between the time March 2005 and September 2005. Two groups were formed; constipation predominant irritable bowel syndrome (IBS-C) patients having co-existence of fibromyalgia (IBS-C plus FMS group, 28 female patients) and IBS-C patients without fibromyalgia (IBS-C group, 28 female patients). Turkish brief version of WHOQOL (World Health Organization Quality of Life) named as WHOQOL-BREF-TR scale was used to determine the QoL of patients. Visual anolog scale was used to determine the severity of pain. Tegaserod 6 mg tablet was given to the study groups administered ½ hours before breakfast and dinner. They were called for control visits at the first and second months of therapy. WHOQOL-BREF-TR scale was answered by patients during these visits. Results. When the total QoL scores of the study groups were compared, there was no difference between the pretreatment values of study groups. But we found a significant difference when the first and second month values of the study groups were compared. (p<0.05). Conclusions. QoL increased in only IBS-C patients but not in patients with a co-existence of fibromyalgia and IBS-C. The reason for this result can be explained by scale related problems as it only determines psychological, environmental and social areas and social and psychological additional support therapies could be required for IBS-C and FMS patients. Although there was no cardiovascular side effects of tegaserod in our study subjects, the drug was withdrawn from market in 2007.
Açıklama
Anahtar Kelimeler
Kaynak
Cumhuriyet Tıp Dergisi (ELEKTRONİK)
WoS Q Değeri
Scopus Q Değeri
Cilt
31
Sayı
1
Künye
ÇAKIR İ,SEÇKİN Y,YÖNEM Ö,KILIÇLI F (2009). The effect of tegaserod on quality of life in patients having co-existence of irritable bowel syndrome and fibromyalgia. Cumhuriyet Tıp Dergisi (ELEKTRONİK), 31(1), 22 - 30.
